Word: nissen
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Renowned heart scientist Dr. Steven Nissen of the Cleveland Clinic, lead author of the study, analyzed what happened to 15,560 patients who were given Avandia and 12,283 in a control group. Using data from already published studies, Nissen found 86 myocardial infarctions in the group that took rosiglitzone, the chemical name for Avandia, compared with 72 in the control group. The number of deaths from heart disease was also higher - 39 among people who took the drug, compared to 22 for the control group. A few dozen deaths out of more than 15,000 subjects may seem small...
...Nissen acknowledges the limitations of his data, but writes that because the drug is so widely used, and because this population is so vulnerable to heart disease, anything that increases their risk of heart attacks is "worrisome" and warrants further study. Nissen tells TIME that he started looking into Avandia because he was concerned by the data in two of the largest studies of patients taking the drug. "The cardiovascular events were all going the wrong direction," he says. Though the results weren't statistically significant, they pushed him to look at other data sets, including studies...
...results of Nissen's research were troubling enough that the Journal, in an editorial accompanying his article, concluded that "the rationale for prescribing rosiglitazone at this time is unclear." The cardiovascular risks simply outweigh any benefit the drug appears to give in treating diabetes, the editorial says, and the FDA should now take regulatory action. With more than 1.5 million new cases of Type 2 diabetes each year in the U.S. and Avandia a mainstay in their treatment, 60 million prescriptions have been written since the drug was introduced...
...GlaxoSmithKline shares took an immediate hit from the release of Nissen's study, falling 7.85% on Monday, with more than 11 million shares - nine times the usual trading volume - changing hands. Investors, not surprisingly, were spooked by the doubts raised about Avandia, which accounted for $3.2 billion in sales last year for GSK. The company went on the offensive almost immediately, releasing a statement criticizing Nissen's research methods. "GSK strongly disagrees with the conclusions reached in the NEJM article, which are based on incomplete evidence and a methodology that the author admits has significant limitations," read the statement. Mary...
...however, moved quickly to respond to what it called "a potential safety issue related to Avandia," issuing a safety alert on the drug just hours after Nissen's study was made public. While the agency pointed out that other studies of the drug have reached different conclusions, it nonetheless will take up the issue of the cardiovascular risk of Avandia and similar drugs with an advisory committee "as soon as one can be convened." Earlier data about Avandia prompted the FDA to strengthen the drug's warning label last year. The FDA also disclosed that GSK recently provided...